Disseminated intravascular coagulation following administration of sunitinib
- Authors:
- Anaëlle Olivo
- Nicolas Noël
- Benjamin Besse
- Anne‑Marie Taburet
- Olivier Lambotte
View Affiliations
Affiliations: Department of Clinical Pharmacy, Bicêtre Hospital, AP‑HP, F‑94270 Kremlin Bicêtre, France, Internal Medicine and Clinical Immunology Department, Bicêtre Hospital, AP‑HP, F‑94270 Kremlin Bicêtre, France, Université Paris Sud, Kremlin Bicêtre, F‑94270 Kremlin Bicêtre, France
- Published online on: May 11, 2016 https://doi.org/10.3892/mco.2016.896
-
Pages:
121-123
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Sunitinib is an increasingly used, orally administered targeted therapy, approved by the European Medicines Agency for the treatment of various types of cancer, including gastrointestinal stromal tumor unresectable or metastatic disease, following disease progression or intolerance to imatinib, and advanced or metastatic renal cell carcinoma, progressive well-differentiated pancreatic neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease. Sunitinib inhibits several tyrosine kinases, including the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor. Tyrosine kinases inhibitor therapies are generally well‑tolerated; nonetheless, they are not void of side effects. The majority of patients reported are grade 1 or 2, and include common and unspecific adverse events, including fatigue, gastrointestinal disorders, skin discoloration, altered taste, cough and dyspnea. Grade 3 or 4 adverse events, including bleeding and hemorrhage, are less frequent. The present study presented the first case of disseminated intravascular coagulation associated with the administration of sunitinib, shortly following the increase of sunitinib dosage.
View References
|
1
|
Aparicio-Gallego G, Blanco M, Figueroa A,
García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E and
Antón-Aparicio L: New insights into molecular mechanisms of
sunitinib-associated side effects. Mol Cancer Ther. 10:2215–2223.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kollmannsberger C, Soulieres D, Wong R,
Scalera A, Gaspo R and Bjarnason G: Sunitinib therapy for
metastatic renal cell carcinoma: recommendations for management of
side effects. Can Urol Assoc J. 1:S41–S54. 2007.PubMed/NCBI
|
|
3
|
Je Y, Schutz FA and Choueiri TK: Risk of
bleeding with vascular endothelial growth factor receptor
tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic
review and meta-analysis of clinical trials. Lancet Oncol.
10:967–974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar R, Crouthamel MC, Rominger DH,
Gontarek RR, Tummino PJ, Levin RA and King AG: Myelosuppression and
kinase selectivity of multikinase angiogenesis inhibitors. Br J
Cancer. 101:1717–1723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giles FJ, O'Dwyer M and Swords R: Class
effects of tyrosine kinase inhibitors in the treatment of chronic
myeloid leukemia. Leukemia. 23:1698–1707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levy M: Disseminated intravascular
coagulation: What's New? Crit Care Clin. 21:449–467. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valle JW, Faivre S, Hubner RA, Grande E
and Raymond E: Practical management of sunitinib toxicities in the
treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev.
40:1230–1238. 2014. View Article : Google Scholar : PubMed/NCBI
|
